Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Translational Validation Trial-B: neoadjuvant FOLFOX in advanced rectal cancer
2011-004228-37Phase 2Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Apr 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid and oxaliplatin in rectal cancer, sponsored by Universitätsmedizin Göttingen. Primary endpoint: toxicity. Started Apr 2012; status: completed.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2011-004228-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004228-37.